<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077427</url>
  </required_header>
  <id_info>
    <org_study_id>115-09</org_study_id>
    <secondary_id>2008-004802-14</secondary_id>
    <secondary_id>AIO-PAK-0111</secondary_id>
    <nct_id>NCT01077427</nct_id>
  </id_info>
  <brief_title>Hyperthermia European Adjuvant Trial</brief_title>
  <acronym>HEAT</acronym>
  <official_title>A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen, Grosshadern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The European Society for Hyperthermic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen, Grosshadern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement of the clinical outcome in patients with resectable pancreatic carcinoma through
      an intensified adjuvant treatment with gemcitabine, cisplatin and regional deep hyperthermia
      as compared to standard chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 60 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>Permanent assessment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Permanent assessment</time_frame>
    <description>EORTC QLQ C30</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Resected Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine + Cisplatin + regional hyperthermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gemcitabine + Cisplatin + regional hyperthermia</intervention_name>
    <description>Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)
Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²)
Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course
* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17</description>
    <arm_group_label>Gemcitabine + Cisplatin + regional hyperthermia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Capecitabine</intervention_name>
    <description>Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)
Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles</description>
    <arm_group_label>Gemcitabine + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any ductal adenocarcinoma of the pancreas confirmed by histology

          2. Previous R0 or R1 resection of pancreatic tumor with a standardized procedure

          3. No other previous or concomitant treatment of pancreatic carcinoma like radiation,
             neoadjuvant therapy or immunotherapy

          4. No tumor recurrence after surgery

          5. Performance status ECOG 0-2

          6. Adequate bone marrow function defined as

               -  WBC count ≥ 3.5 x 109/L and

               -  platelets ≥ 150 x 109/L and

               -  haemoglobin ≥ 9 g/dl documented within 1 week prior to randomization

          7. Adequate renal function defined as

               -  serum creatinine ≤ 1.2 mg/dL and

               -  calculated GFR ≥ 60 mL/min documented within 1 week prior to randomization

          8. Adequate coagulatory function defined as

               -  Quick-value ≥ 70% and

               -  aPTT ≤ 1.5 x ULN documented within 1 week prior to randomization

          9. Transaminases (AST, ALT) ≤ 3 x ULN and bilirubin ≤ 2 x ULN documented within 1 week
             prior to randomization

         10. At least 18 years of age

         11. Women with childbearing potential and fertile men must use adequate contraceptive
             measures during and for at least 3 months (female) and 6 months (male) after
             completion of study therapy (Adequate methods for women are oral contraceptives with
             estrogen and progesterone, vaginal rings, contraceptive patches, estrogen-free
             ovulation inhibitors, intrauterine devices with progesterone, 3-month injections with
             depot progesterone, implants setting free progesterone, abstinence or sterilization
             (vasectomy) of the male partner. Men must use condoms.)

         12. Women with childbearing potential must have a negative pregnancy test within 1 week
             prior to randomization (postmenopausal women with amenorrhea for more than 1 year are
             regarded as having no childbearing potential)

         13. Written informed consent

        Exclusion criteria:

          1. Cystic carcinoma of the pancreas

          2. Periampullary, papillary cancer

          3. Metastatic disease

          4. Presence of an active infection grade 3 or higher

          5. Other severe disease which could impair the patient's ability to participate in the
             study according to the investigator's opinion

          6. Pregnant or breastfeeding women

          7. Known allergies or contraindications with regard to substances or procedures of study
             therapy

          8. Severe, non-healing wounds, ulcers or bone fractures

          9. Participation in another clinical trial during this study or within 4 weeks prior to
             randomization (Exception: participation in a surgical trial prior to this study, for
             instance RECOPANC trial, comparing two different surgical procedures of pancreas
             resection)

         10. Past or current abuse of illegal or legal drugs or alcohol

         11. Other primary malignant diseases in the medical history during the last 5 years
             (exceptions: carcinoma in situ of the cervix or adequately treated basal cell
             carcinoma of the skin).

         12. Permanent cardiac pacemaker

         13. Clinically significant cardiovascular or vascular disease or disorder ≤ 6 months
             before study enrolment (e.g. myocardial infarction, unstable angina pectoris, chronic
             heart failure NYHA ≥ grade 2, uncontrolled arrhythmia, cerebral infarction

         14. Gross adiposity defined as BMI &gt; 40 kg/m²

         15. Treatment with regional hyperthermia not possible for technical reasons (e.g. metal
             implant)

         16. &quot;Known documented dihydropyrimidine dehydrogenase (DPD) deficiency&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf D. Issels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Grosshadern, Medical Center, University of Munich, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolf D. Issels, MD, PhD</last_name>
    <phone>+49-89-4400-77776</phone>
    <email>heat@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Grosshadern, Medical Center, University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf D. Issels, MD, PhD</last_name>
      <phone>+49-89-4400-77776</phone>
      <email>heat@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Rolf D. Issels, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.pankreaszentrum-muenchen.de</url>
    <description>Pankreaszentrum München</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen, Grosshadern</investigator_affiliation>
    <investigator_full_name>Rolf D. Issels</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>hyperthermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

